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There is a need for biomimetic materials for use in blood-contacting devices. Blood contacting 
surfaces maintain their patency through physico-chemical properties of a functional endothelium. A 
poly(carbonate-urea) urethane (PCU) is used as a base material to examine the feasibility of L-Arginine 
methyl ester (L-AME) functionalized material for use in implants and coatings. The study hypothesizes 
that L-AME, incorporated into PCU, functions as a bioactive porogen, releasing upon contact with blood 
to interact with endothelial nitric oxide synthase (eNOS) present in blood. Endothelial progenitor cells 
(EPC) were successfully cultured on L-AME functionalized material, indicating that L-AME -increases cell 
viability. L-AME functionalized material potentially has broad applications in blood-contacting medical 
devices, as well as various other applications requiring endogenous up-regulation of nitric oxide, 
such as wound healing. This study presents an in-vitro investigation to demonstrate the novel anti-
thrombogenic properties of  L-AME, when in solution and when present within a polyurethane-based 
polymer.
There is a need for biomimetic materials, which can resist thrombosis associated with blood contacting devices 
which include1; cardiovascular implants, such as vascular bypass grafts, synthetic heart valves, vascular access 
devices, cardiac patches, coatings for stents, pacemakers as well as implants for wound healing. Several materials 
currently in clinical use such as polytetrafluoroethylene (ePTFE), polyethylene terephthalate (Dacron® ) and pol-
yurethane are suboptimal2, and often lead to graft failure due to their inherent thrombogenic nature3. Ideal mate-
rials should possess suitable mechanical properties that provide the required structural support, and mimic the 
properties of the endothelium; the inner-most blood-contacting tissue in the cardiovascular system. The endothe-
lium, maintains smooth blood flow and nitric oxide (NO) is a key player. NO has the ability to inhibit platelet 
aggregation and activation, and produce smooth muscle relaxation through activation of the cyclic guanylate 
monophosphate (cGMP) pathway4. It also inhibits smooth muscle cell proliferation. Moreover, NO aids endothe-
lialization, wound healing; although the mechanism in unclear, it has been shown to promote re-epithelialization 
and collagen formation, as well as angiogenesis5.
L-Arginine (L-Arg), a commonly occurring amino acid, is an endogenous substrate of nitric oxide synthase 
(NOS)6, a family of enzymes including neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS 
(iNOS), which all catalyze the formation of NO (along with citrulline) from L-Arg7. L-Arg therefore possesses 
anti-thrombogenic properties. eNOS produces the majority of the NO within the vascular system, and is present 
in red blood cells, which means that NO can be produced even in the absence of an endothelium8,9. Hence, L-Arg 
is important in cardiovascular physiology, and L-Arg supplementation in individuals with hypercholesterolemia 
or atherosclerosis has been shown to improve endothelial function, dependent upon L-Arg concentration and the 
type of cardiovascular disease10 There are many analogues of L-Arg that also affect the activity of NOS; L-arginine 
methyl ester (L-AME) has a very similar chemical structure to L-Arg (Fig. 1a). Although L-AME has relatively 
low iNOS activity (compared to L-Arg), there have been several studies where L-AME is reported as a substrate 
for NOS11–14.
L-AME is highly soluble in water, and crystalizes when precipitated from solution. It can therefore be used as 
an effective porogen when incorporated, in dissolved form, into the bulk of a polymer; following crystallization 
within the polymer, L-AME can be removed, leaving behind a porous matrix. If left within the polymer, the 
resulting material would possess the hydrophilic properties of L-AME. Porosity is a highly favorable property 
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for surgical implants, as it facilitates cell-material interactions as well as angiogenesis through the movement of 
molecules and nutrients within the polymeric scaffold15,16.
Elastomers are widely used for surgical implants due to their inherent mechanical properties17,18, which can 
be adjusted for a range of applications, as well as their ability to act as a host to cell-integrating molecules that can 
confer biocompatibility when applied as an implant.
In this study, a poly(carbonate-urea) urethane (PCU) is used as a base material and carrier to examine the 
feasibility of producing an L-AME functionalized material for use in implants and coatings19,20. It was therefore 
hypothesized that L-AME, incorporated into PCU, would function as a bioactive porogen, releasing upon contact 
with blood to interact with eNOS present in blood cells/platelets, resulting in an anti-thrombogenic effect. Base 
material, carrying the bioactive molecule was characterized for the homogenous presence of the L-AME and 
its physico-chemical properties, before and after the elution of the bioactive molecule. Whole blood kinetics of 
L-AME were determined, and L-AME-PCU (L-AME-P) was examined in-vitro for its cell-material interaction 
potential, for blood-contacting surgical implants.
Results
Biofunctionalization of the polyurethane based polymer with L-AME. Materials fabricated (as 
demonstrated in Fig. 2) were tested for successful encapsulation, and homogenous distribution of L-AME within 
the base material, with both qualitative and quantitative tests.
The Kaiser test was used to qualitatively observe the presence of primary amine groups through a distinct color 
change in the presence of L-AME relative to the PCU control21. The guanidine group, present on L-AME is identical 
to that present in L-Arg (Fig. 1). As the functional group is required for L-Arg to be active through the NOS pathway, 
theoretically its presence allows L-AME to possess the same characteristic7,11–14. Fig. 3a(i) shows the unmodified 
PCU control, in the presence of the reagents, with a non-significant color change, relative to the polymer in the 
Figure 1. The chemical structures of L-arginine (L-Arg) and L-arginine methyl ester (L-AME). The 
guanidine group, present in both structures, has been highlighted on L-AME.
Figure 2. L-AME-P synthesis: Physical entrapment method. Cast method (1) L-AME combined with PCU 
(dissolved in DMAc solvent) (2) L-AME-P slurry poured into glass container (3a) Container placed into oven at 
60 °C for 24 hours (4a) DMAc evaporates from solution (5a) L-AME-P produced.
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Figure 3. (a) Kaiser test on polymer; coloration indicated the presence of primary amine groups, and so 
confirms the presence of L-AME: (i) POSS-PCU control – A hint of purple coloration (ii) 0.40 M L-AME-P – 
Distinct overall color change to purple (iii) 0.75 M L-AME-P – Overall color change to deeper purple (iv) 1.05 M 
L-AME-P – Distinct overall color change to deep purple/black, corresponding to the higher concentration 
of L-AME. (b) Superimposed (matched y-axis magnitude) FTIR spectra for POSS-PCU with increasing 
concentrations of incorporated L-AME: POSS-PCU control and 0.40 M/0.75 M/1.05 M L-AME + POSS-PCU. 
The spectra produced suggest the presence of L-AME with an N-H stretch (3500 − 3300 cm−1) and an N-H 
bend (1650–1580 cm−1) indicating the presence of primary amine groups, with a dependent change in the 
absorbance at these wavelengths, where an increase in L-AME concentration resulted in an increase in relative 
absorbance. (c) ToF-SIMS analysis of the polymer combined with XPS analysis. Images were constructed for 
the positive ion at m/z 189. The images show a uniform distribution of the L-AME as well as an increase in 
ion intensity with the concentration used in the preparation of the surfaces: (i) Positive ion image of m/z 189 
(C7H17N4O2+) for the POSS-PCU control. The scale is offset so all images have the same scale (MC = 5).  
(ii) Positive ion image of m/z 189 (C7H17N4O2+) for 0.40 M L-AME-P. The scale is offset so all images have the 
same scale (MC = 5). (iii) Positive ion image of m/z 189 (C7H17N4O2+) for 0.75 M L-AME-P. (iv) Positive ion 
image of m/z 189 (C7H17N4O2+) for 1.05 M L-AME-P.
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absence of the reagents. Fig. 3b(ii) shows 0.40 M L-AME + PCU, with a distinct overall color change, indicating the 
presence of L-AME. Furthermore 0.75 M L-AME-P (Fig. 3a(iii)) and 1.05 M L-AME-P (Fig. 3a(iv)) each displayed a 
distinct color change to deep purple (almost black), relative to the control, indicating the presence of L-AME.
The presence of the amine groups was further confirmed through FTIR. Figure 3b shows the superimposed 
(matched y-axis magnitude) IR spectrum for a range of L-AME concentrations incorporated into PCU, and suggests 
the presence of L-AME with an N-H stretch (3500 − 3300 cm−1) and an N-H bend (1650 − 1580 cm−1) indicating 
the presence of primary amine groups, with a concentration dependent change in the absorbance at these wave-
lengths, where an increase in L-AME concentration resulted in an increase in relative absorbance.
ToF-SIMS analysis of the polymer combined with XPS analysis confirmed that L-AME was homogenously 
distributed within the polymer matrix, with a positive correlation between the concentration of L-AME used and 
the intensity of the observed peaks. Several of those found in the positive spectrum were the ions at m/z 100, 101 
and 127. The ion at m/z 189 was used as a marker for L-AME due to its high intensity. Images were constructed 
for the peak at m/z 189 (Fig. 3c). XPS data showed a positive correlation between the N+ peak at 401.6 eV of the 
N 1 s signal with the concentration of L-AME-P. The peak at 401.6 eV corresponds to positively charged nitro-
gen (NH3+). The positively charged nitrogen, arising from L-AME, rises with the concentration of incorporated 
L-AME. The respective number of N atoms in the base polymer matrix and L-AME, allowing determination of 
the L-arginine-polymer ratio NR/NPol, where a positive correlation was observed, between the L-arginine-polymer 
ratio NR/NPol and the concentration of incorporated L-AME.
L-AME, incorporated through physical entrapment, was expected to be contained within the carrier polymer 
via electrostatic attraction. Figure 4b shows 0.40 M L-AME-P, which has a continuous surface, with the presence 
of L-AME in cavities under the surface of the polymer. Figure 4d, with 1.05 M L-AME-P has a distinctly different 
surface from the other L-AME concentrations; (Fig. 4b,c) with protruding areas, roughly hexagonal in shape, and 
around 2 μ m in diameter.
Contact angle measurements using the static sessile drop method demonstrated that these functionalized 
polymers were hydrophilic in the presence of L-AME. The difference in mean contact angle for each L-AME 
concentration incorporated within the base polymer was significantly different (p < 0.001) from each other con-
centrations, ranging from 101.3° for the control to 70.1° for the highest concentration of incorporated L-AME. 
Figure 5 shows a concentration dependent, inversely proportional, trend in the mean contact angle for increas-
ing concentrations of L-AME, causing an increase in hydrophilicity, supported by linear regression analysis 
(r2 = 0.958, p < 0.001). Following L-AME elution, the material reverted to becoming hydrophobic, with no 
significant association between initially incorporated L-AME concentration and surface wettability. (r2 = 0.037, 
p < 0.295).
The total amount of L-AME contained within a test scaffold of L-AME-P was found by calculation to be 
1.87 mg (0.40 M), 3.73 mg (0.75 M), and 5.60 mg (1.05 M). OPA assay was used to determine the amount of 
L-AME eluting from the polymer. The 0.4 M scaffolds eluted at an initial rate of 59.4 (±1.7) μ g min−1 (after 10 min-
utes) before the rate became immeasurable. The 0.75 M discs eluted at an initial rate of 143.6 (±2.4) μ g min−1  
(after 10 minutes), and then dropped to a rate of 11.2 (±1.0) μ g min−1 after 20 minutes before the rate became 
immeasurable. The 1.05 M scaffolds, (which was the highest concentration) eluted at an initial rate of 230.5 
(±2.0) μ g min−1, and had dropped to 0.14 (±0.01) μ g min−1 after 42.67 hours.
Figure 4. Surface of PCU with increasing concentration of L-AME incorporated without elution, magnified 
at 5000x: (a) PCU control (b) 0.40 M L-AME-P (c) 0.75 M L-AME-P (d) 1.05 M L-AME-P. Surface of PCU 
following elution of L-AME from the polymer matrix, magnified at 5000x: (e) PCU control (f) 0.40 M L-AME-P 
(g) 0.75 M L-AME-P (h) 1.05 M L-AME-P. Incorporation, and subsequent elution, of L-AME produced a 
porous structure, with an increase in initially incorporated L-AME causing an increase in pore size, with the 
higher concentrations developing a honeycomb-like porous structure. POSS nanoparticles are present on the 
surface of all samples of polymer as the polyurethane used in the study is a nanocomposite of PCU.
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Figure 4e is the scanning electron microscopy of PCU control, which was treated in the same conditions as 
to elute L-AME from L-AME-P. The surface of this control remained uninterrupted, with POSS crystals present 
on the surface-a component of the polyurethane composite used in this study. 0.40 M L-AME-P sample after 
complete elution of L-AME (Fig. 4f) had a surface covered with shallow pores. The average pore diameter for the 
0.40 M L-AME structure was 1.59 μ m (±0.33 μ m), and the pore density was 1.00 × 108 mm−2. 0.75 M L-AME-P 
(Fig. 4g) developed a deeper porous structure, with an average pore diameter of 2.74 μ m (±0.58 μ m), and a pore 
density of 6.98 × 107 mm−2. 1.05 M L-AME-P also developed a honeycomb-like porous structure, with an average 
pore diameter of 2.95 μ m (±0.83 μ m), and a pore density of 6.01 × 107 mm−2 (Fig. 4h). The porous structure was 
most likely produced by re-crystallization of L-AME within the polymer substance, following the evaporation 
of the solvent during the polymer casting process. There was a significant correlation between the L-AME con-
centration and pore size (R2 = 0.494, p < 0.001); as the incorporated concentration of L-AME was increased, 
the pore size increased, which is different to the most common occurrence with porogen, where the pore size is 
determined by the size of the porogen molecule22. With L-AME-P, the pore density significantly decreased with 
an increase in incorporated L-AME (R2 = 0.844, p < 0.001).
The control had a higher maximum stress of 66.4 MPa and a similar percentage elongation at break of 740.4%. 
In general, an increase in incorporated L-AME caused a decrease in mechanical strength, with the lowest max-
imum strength (42.6 ± 3.79 MPa) of 1.05 M L-AME and strain at break (634.6 ± 86.3%) of 0.75 M L-AME. 
The elution of L-AME caused a decrease in the modulus of the polymer, with the lowest maximum strength 
(34.3 ± 4.85 MPa) and strain at break (555.6 ± 55.1%) for 1.05 M L-AME.
Cell-material interactions of the bioactive scaffolds. Whole Blood Kinetics with 
Thromboelastography. The control, (in the absence of L-AME), demonstrated the lowest time until clot for-
mation initiated (SP) at 8.38 mins, until the clot reached 2 mm in amplitude (R) at 9.75 mins, and until the clot 
reached 20 mm in amplitude (K) at 3.45 mins. The control also had the highest angle at 48.78o, with maximum 
amplitude of clot formation at 57.38 mm, and G of 7027 d/sc. 191 mM L-AME solution had the highest SP time, 
R, and K at 17.42 mins, 20.33 mins, and 7.52 mins respectively. 191 mM L-AME solution also had the lowest angle 
at 27.78o, maximum amplitude of 47.70 mm, and clot strength (G) of 4612 d/sc.
There were found to be significant differences across all measured variables, with the results summarized 
in Table 1. L-AME, a recognized analogue of L-Arg, has been reported as a NOS substrate11,23,24. This was con-
firmed by our group, by performing TEG tests with relevant L-AME samples with the blood of eNOS knockout 
mice, kindly provided to us by Prof Adrian Hobbs’s group (QMUL) as a collaboration study. The unpublished 
results, which led us to the current study examining L-AME, demonstrated that the concentration-dependent 
anti-thrombogenic effect was not evident in the presence of eNOS knockout blood and the TEG parameters had 
no significant differences across the varied concentrations.
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Figure 5. Mean Contact Angle (Theta) of water on the surface of L-AME-P with increasing concentration 
of incorporated L-AME, ranging from the PCU control to 1.05 M L-AME. L-AME present: An increase in 
incorporated L-AME caused a significant decrease in the surface contact angle, supported by linear regression 
analysis (R2 = 0.958, p < 0.001). L-AME eluted material: No statistical relation between initially incorporated 
L-AME concentration and surface contact angle (p = 0.295).
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L-AME-P samples were found to have significant differences across all measured variables, summarized in 
Table 2.
The control polyurethane had the lowest SP time, R and K at 9.30 mins, 10.63 mins and 2.97 mins respectively. 
The control also had the highest angle at 51.57o, with maximum amplitude of 59.67 mm and G of 7397 d/sc. 
1.05 M L-AME-P had the highest SP time, R, and K at 21.47 mins, 25.10 mins and 7.03 mins respectively. 1.05 M 
L-AME-P also had the lowest angle at 30.07o, maximum amplitude of 52.50 mm, and a clot strength of 5538 d/sc.
Cell-Material Interactions on L-AME Functionalized Scaffolds. Endothelial progenitor cells (EPC), which were 
isolated from blood, and cultured for 10 days on scaffolds of increasing L-AME concentrations, indicated that the 
presence of L-AME significantly increases cell viability (Fig. 6a). On the fifth day, at the higher concentrations 
of L-AME (0.75 M, 1.05 M ), L-AME significantly improved cell viability when compared with both the control 
and washed samples, showing that the honeycomb structure of the polymer has a less significant role for this 
particular cell-type. At day 10, cell-viability followed a significant L-AME concentration-dependent response. 
Furthermore, the highest 1.05 M L-AME concentration significantly increased cell-metabolic activity at a higher 
rate compared to the eluted sample (1.05 M eluted) and the control (SI Fig. 1). Scaffold porosity appeared to 
significantly improve cell-viability at 1.05 M and 0.40 M L-AME. Immunohistochemistry images (Fig. 6b) support 
the cell viability data and the characteristic EPC colonies are prominent and much more dense in the highest 
L-AME concentrations.
Fibroblasts were cultured on L-AME-P scaffolds for 72 hours to investigate the potential for application in 
wound-healing devices, while endothelial progenitor cells were used to investigate the potential for application 
in a vascular device. Results (Fig. 6c) from this cell-type indicate that the lowest concentration, 0.40 M L-AME, 
is optimal for fibroblast viability, showing a significant difference at 72 hours. In both time-points tested, scaffold 
porosity seemed to significantly increase cell-viability compared to the untreated scaffold. Furthermore, immu-
nohistochemistry images (Fig. 6d) support the Alamar Blue assay data and show favorable interaction with the 
porous scaffold.
Discussion
This study, for the first time, has demonstrated the anti-thrombogenic properties of an L-arginine analogue, 
L-AME, the potential for its incorporation into a polyurethane based polymeric carrier, and its influence as a 
porogen on the carrier material for cell material interactions. The presence of L-AME was confirmed by identi-
fying the primary amine group through distinct color changes, with increasing L-AME concentrations. Further 
quantitative confirmation was carried out using FTIR, that showed a dependent change in the absorbance at 
the demonstrated wavelengths, where an increase in L-AME concentration resulted in an increase in relative 
L-AME 
Concentration (mM)
SP (min) One-way 
ANOVA p < 0.001
R (min) One-way 
ANOVA p < 0.001
K (min) One-way 
ANOVA p < 0.001
Angle (deg) One-way 
ANOVA p < 0.001
MA (mm) One-way 
ANOVA p = 0.045
G (d/sc) One-way 
ANOVA p = 0.031
0 (Control) 8.38 9.75 3.45 48.78 57.38 7027
19 9.85 11.33 3.52 47.18 56.03 6505
38 11.43 12.75 4.13 44.68 54.67 6194
57 12.22 14.15 4.72 39.18 51.18 5350
77 12.48 14.37 5.23 36.75 51.43 5333
115 13.08* 15.33* 5.43 35.18 50.32 5123
153 16.48* * * 19.05* * * 6.72* * 30.55* * 49.48 4984(a)
191 17.42* * * 20.33* * * 7.52* * * 27.78* * * 47.70 4612(a)
Table 1.  Summary of thromboelastography results for increasing concentrations of L-AME in solution. 
n = 6. One-way ANOVA showed a significant difference between concentrations for each variable. Bonferroni 
post-hoc test showed significant differences for concentrations relative to the control. * p < 0.05 * * p < 0.005  
* * * p < 0.001 (a)n = 5 due to incomplete Thromboelastography tests.
L-AME 
Concentration (M)
SP (min) Kruskal-
Wallis p = 0.01
R (min) Kruskal-
Wallis p = 0.005
K (min) Kruskal-
Wallis p = 0.012
Angle (deg) One-way 
ANOVA p < 0.001
MA (mm) One-way 
ANOVA p = 0.002
G (d/sc) One-way 
ANOVA p = 0.002
0.00 (Control) 9.3 10.63 2.97 51.57 59.67 7397
0.4 11.73 13.2 3.67 45.83 55.7 6287
0.75 15.53 18.23 5.07 36.03* 54.87 6081* 
1.05 21.47* 25.10* 7.03 30.07* * 52.50* * 5538* * 
Table 2.  Summary of Thromboelastography results for increasing concentrations of L-AME incorporated 
into POSS-PCU polymer. n = 3. Kruskal-Wallis Test and one-way ANOVA showed a significant difference 
between concentrations for each variable. Pairwise comparisons (Kruskal-Wallis) and Bonferroni post-hoc 
(after ANOVA) test showed significant differences for concentrations relative to the control. * p < 0.05  
* * p < 0.005 * * * p < 0.001.
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Figure 6. (a) EPC viability analysis (O.D values ± SD) by Alamar Blue at day 5 and day 10.  
(b) Immunohistochemistry images at day 5 for 1.05 M L-AME present and washed. Cell nuclei were stained 
with DAPI (blue) and actin was stained by phalloidin (green). (c) Fibroblast viability analysis (O.D values ± SD) 
by Alamar Blue at 36 h and 72 h. (d) Immunohistochemistry images at 36 h and 72 h for 0.40 M L-AME present 
and washed. Cell nuclei were stained with DAPI (blue) and actin was stained by phalloidin (green). * p < 0.05 
Bonferroni shows statistical significance.
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absorbance. Moreover, L-AME proved to be homogenously distributed within the polymer matrix, with a positive 
correlation between the concentration of L-AME used and the intensity of the observed peaks.
Hydrophilicity is an important feature for synthetic vasculature, as it can prevent platelet adhesion25,26, 
and so alter fibrinogen adsorption, and promote endothelialization, which are all crucial for long-term graft 
patency15,27–29. A prompt release response within L-AME-P in the presence of a hydrophilic environment is highly 
favorable as the patency of blood contacting implants are influenced by the proteins encountered immediately 
after implantation, governed by the Vroman effect19,23. Following L-AME elution, the material reverted to its orig-
inal state of surface wettability thus suggesting that the increase in hydrophilicity was due to the presence of an 
increasing concentration of L-AME. However, it is recognized that the determination of hydrophobicity of porous 
structures through contact angle measurements is less reliable as the measurements are influenced by the surface 
property of the porous structure with the capillary forces as well as roughness and microstructures within pores. 
However comparison with a single porogen as used here reduces this variability. Thromboelastography studies 
performed on L-AME eluted, porous scaffolds demonstrated no difference when compared with unmodified 
polyurethane, suggesting that the anti-thrombognic properties observed are due to the presence of L-AME, but 
homogenous pore structures, which are less than 5 μ m diameter (Fig. 4) induced by L-AME elution had negligible 
influence in thrombogenicity.
A controlled, steady, and sustained release of L-AME is desirable, preferably at a rate that enables the biolog-
ical processes to support graft patency through biomimicry of a functional blood-contacting tissue. For further 
study, an area of interest would be to examine the modification of L-AME release simultaneously with other 
known anti-thrombogenic molecules that influence the levels of NO, or endothelialization for further applica-
tions30,31. Further work should also examine techniques such as the production of multi-layered polymers, or 
microencapsulation of molecules, to facilitate prolonged, sustained release of L-AME32.
Porosity is also an important topographic feature for cell-material interactions within a scaffold15. In the lowest 
concentration of L-AME-P, the pores were distinct, but separate. In the polymer with the highest concentration 
of incorporated L-AME however, the structure showed interconnection between the pores. The even distribution 
of pores across the surface produced a honeycomb-like structure, as the pore distribution and inter-pore distance 
is potentially as important as pore size20,22,33–35 proved to be ideal for cell seeding. The concentration-dependent 
changes of porosity observed here presents the possibility of producing custom scaffolds, of desired pore dimen-
sions, for a given application.
Favorable mechanical properties are one of the advantages of using polyurethane based materials for surgical 
implants33. The mechanical properties of the polyurethane base used in this study, were comparable to those 
from a previous study19,36. Following L-AME incorporation, a decrease in strength noted in comparison with 
the control, but yet it is still more than sufficient to withstand the mechanical stresses that the material would be 
subjected to in an in vivo environment15.
The experimental procedures currently undertaken to determine blood compatibility of biomaterials are 
somewhat controversial and is a subject of discussion amongst researcher as well as policy makers37,38.
Traditionally, standardized blood compatibility tests are classified into five categories: thrombosis, blood coag-
ulation, platelets function, hematology and complement system39.
Thromboelastography is a more complete method of coagulation testing than other plasma-based alterna-
tives40,41, and proved the potent anti-thrombogenic properties of L-AME42. Thromboelastography by using whole 
blood incorporates all cellular elements involved in the hemostatic process, including platelets, red cells and 
white blood cells thereby giving a more global representation of the coagulation process as it occurs in vivo. 
In detail, the results demonstrated, that the effect is primarily on the plasmatic component (SP and R – Table 3) 
with less activation of coagulation at the higher concentrations used. There are also significant effects observed 
with K and alpha angle (Table 3), which are related to the rate, amount and speed of thrombin generation, and in 
the case of alpha angle, also the rate at which fibrin crosslinking occurs. The significant differences indicate that 
thrombin generation is significantly attenuated and thus the material is less thrombogenic. The relatively small 
impact on the MA (function of fibrinogen and platelets), indicated that it is likely that there is no significant 
reduction (or increase) in platelet reactivity.
Parameter Abbreviation Measurement Interpretation
Split Point [mins] SP Time until earliest detected resistance
Time to until initial clot 
formation
Reaction time [mins] R Time until 2 mm amplitude
Enzymatic clotting factor 
initiation phase
Coagulation time [mins] K Time from 2 mm–20 mm amplitude
Rate at which clot 
strengthens, representative 
of fibrinogen to fibrin 
cleavage
Angle [degrees] α 
Angle of tangent to 
the line between R 
and K
Maximum amplitude [mm] MA Maximum recorded amplitude of tracing 
End result of platelet-fibrin 
interaction
Clot strength [d/sc] G Calculated from amplitude of tracing Total clot strength
Table 3.  Variables measured from a thromboelastography tracing36.
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L-AME maintained its anti-thrombogenicity when incorporated into the base material, PCU, which is itself 
marked improved upon the hemocompatibility of currently available synthetic materials43. Improved hemocom-
patibility is of paramount importance for maintaining graft patency3,44.
With favorable hemocompatibility and cell-material interaction, implants based on L-AME-P could poten-
tially have successful long-term integration. NOS is weakly stimulated by its substrate under conditions of relative 
substrate abundance, and therefore the ability of L-AME is expected to be relatively greater. It would be of interest, 
in subsequent studies, to look into the detailed pathways of L-AME-initiated anti-thrombogenicity, as well as 
its antiplatelet synergy with others such as clopidogrel and prostacyclin, as well as direct NO donors including 
nitrosothiols and diazeniumdiolates44–46.
The long-term patency of blood contacting surgical implants is preserved in the presence of a functional 
endothelium. In-situ endothelialization is considered the most favorable option, where endothelial progenitor 
cells (EPC) can be exploited29. In the current study, the EPC viability was higher than the control even with the 
lowest concentration of L-AME samples. Furthermore, significantly high cell viability with L-AME eluted scaf-
folds suggest a role for topographical features (Fig. 4) on the EPC cell behavior as material topography is well rec-
ognized to influence cell-material interactions. Thus both the L-AME released from the scaffolds and the porous 
structure of L-AME-P might have a synergistic effect.
Materials for wound healing implants also require favorable blood-material interactions, as well as efficacious 
interactions with EPC, particularly for angiogenesis and arginine has been previously linked to anti-aging and 
wound healing47–49. It was therefore of interest to investigate the growth of fibroblasts on the scaffolds, which had 
already proved to be optimal for hemocompatibility, and EPC growth. This effect of positive influence on rela-
tively low concentrations has been observed previously50.
The results of this study indicate that L-AME possesses great potential for promoting endothelialization 
and wound healing. This suggests that L-AME has a dual effect, by first initiating favorable metabolic cas-
cades, and second, by creating a uniformly porous surface that improves cell adhesion (as shown in our fibro-
blast experiments). Our results further support previous evidence that administration of L-Arginine improves 
wound-healing capacity in mice by activating the NOS pathway and increasing NO- levels49,51. Further work 
could potentially include investigating the internalization pattern of L-AME, and protein expression of NOS. In 
addition, studies could also tests how the surface area of the porous matrix/limiting dimensions of porosity that 
could influence the platelet/fibrinogen adsorption and the protein excretion of the cells, which might be a poten-
tial issue for a long-term vascular implant, in addition to in-vivo investigation of L-AME incorporated material in 
the form of appropriate surgical implants
In conclusion, the results of this study support the hypothesis that L-AME, incorporated into 
polyurethane-based polymer, elutes into a hydrophilic environment, to exhibit an anti-thrombogenic effect. In 
addition, L-AME-incorporated material has demonstrated optimal cell adhesion properties, to support long-term 
cell-materials interactions, for use in surgical implants. As an anti-thrombogenic agent, L-AME has broad appli-
cation in the cardiovascular field, with the potential to increase hemocompatibility for synthetic vascular grafts, 
coated stents, pacemakers, blood gas sensors, and many other blood-contacting medical devices. If L-AME is 
active through NOS, the determination of which must be a priority in further study, it has potential for applica-
tion in wound healing, as well as many other applications that require endogenous up-regulation of NO levels.
Methods
All the chemicals used in this study were obtained from Sigma-Aldrich Co. LLC.
Producing a polyurethane-based polymer with incorporated L-AME (L-AME-P). L-arginine methyl 
ester dihydrochloride (L-AME.2HCl) was dissolved in water (500 μ L) at various concentrations (0–540 mg mL−1), 
and dimethylacetamide (DMAc) (5 g) was then added. Each resulting L-AME.2HCl solution was added to 
18%(w/w) PCU polymer (0.9 g PCU in 4.1 g DMAc). PCU synthesis has been reported previously36. The result-
ing mixture was poured into a circular glass tray (radius = 46 mm), and heated at 60 oC in a circulating oven for 
12 hours to facilitate DMAc evaporation (Fig. 2).
Biofunctionalization of the polyurethane-based polymer with L-AME. O-phthalaldehyde (OPA) 
assay for the determination of L-AME concentration in solution. Fluorescent products are formed through 
the reaction of a primary amine with o-phthalaldehyde52,53. Based upon a previously used method, 83 μ L of 
2-mercaptoethanol solution (25 μ L made up to 4 mL using ethanol) and 883 μ L borate buffer (0.05 mol L−1, titrated 
to pH 9.0) were mixed with 34 μ L of analyte solution. After standing for 2 hours, 34 μ L OPA solution (10 mg made 
up to 1 mL using ethanol) was added to the mixture and the fluorescence was recorded within four minutes 
following mixing. Fluorescence was determined using a Fluoroskan Ascent FL fluorescence plate reader with a 
355 nm excitation filter and a 460 nm emission filter. Values were obtained using a standard curve for absorbance 
against concentration (r2 = 0.948, the standard curve can be found in the Supporting Information, SI Fig. 2).
L-AME elution from L-AME-P. Discs of 0.40 M/0.75 M/1.05 M L-AME-P with a radius of 7.8 mm produced 
using a Trotec 100R laser cutter were placed in a container with 4.0 mL of 0.9% NaCl, and were placed onto a 
roller at 37 °C. Eluents were changed periodically, whilst re-incubating the samples in new containers with 0.9% 
NaCl. OPA assay was performed on the removed eluents to test for the presence of L-AME.
Tensile strength of L-AME-P. Samples of polymer were tested to determine the mechanical strength of the pol-
ymer with increasing concentration of incorporated L-AME (untreated group). It was also determined whether 
elution of incorporated L-AME affected the mechanical properties of the polymer (partial elution group). The 
tensile strength of L-AME + PCU was tested using an Intron 5500 series (5565) Twin Column material testing 
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system and Bluehill® software. The polymer was cut to specification ISO 37 Type 3, and the Instron grips were set 
at a distance of 20 mm. Half of the dumbbells from each L-AME concentration were treated with H2O for seven 
days to allow complete elution of L-AME from the polymer.
Contact angle analysis of L-AME-P surface. Polymer cast onto glass slides was placed into a Kruss DSA 100 to meas-
ure contact angles using the static sessile drop method. 5 μ L of H2O (Ström) was dropped at a rate of 60 μ L min−1 
onto L-AME-P, and the contact angles were measured using Drop Shape Analysis for Windows 1.92.1.1 exactly 
20 seconds after the droplet came into contact with the polymer surface. Two samples were used, with four sepa-
rate measurements taken per sample.
Fourier transform infrared spectrometry (FTIR) of L-AME-P polymer surface. L-AME-P polymer prepared on 
glass slides was analyzed using a JASCO FT/IR-420 spectrometer. 25 scans were performed across the range 
4000 − 600 cm−1 at a resolution of 4 cm−1. Analysis was performed using Essential FTIR 3.10 build 41.
Kaiser test for the presence of L-AME on polymer surface. This qualitative test is based upon the reaction of nin-
hydrin with primary amine groups21. 5% (w/v) ninhydrin solution (1 g made up to 20 mL with ethanol), phenol 
4:1 (w/v) in ethanol, and 2% (v/v) potassium cyanide (0.4 mL of a 1 mmol L−1 aqueous solution of potassium cya-
nide was made up to 20 mL with pyridine) were produced. 100 μ L of ninhydrin solution was added to the surface 
of the L-AME + PCU polymer, followed immediately by 50 μ L of phenol solution, and then 50 μ L of potassium 
cyanide solution. Each treated surface was then photographed using the same settings and external conditions.
Scanning electron microscopy of L-AME-P. Polymer for imaging was either untreated, or washed with de-ionized 
H2O for seven days to allow complete elution of L-AME. A 3 × 3 mm2 section of polymer was placed onto a stub. 
The stubs were inserted into a Quorum Q150 Rotary-Pumped Sputter Coater, which coated the samples with 
gold. The stubs were then placed in a Zeiss Evo HD15 SEM, and the samples were examined.
Time-of-flight Secondary Ion Mass Spectrometry (ToF-SIMS) analysis of L-AME-P. ToF-SIMS uses an ion beam to 
determine the mass of particles on the surface of a solid material54. Samples of polyurethane-based polymer with 
increasing concentration of incorporated L-AME were cast onto glass slides for surface analysis. The TOF-SIMS 
analyses were executed using an ION-TOF TOF-SIMS IV instrument (Munster, Germany), equipped with a Bi 
LMIG. Stage scans with 256 pixels mm−1 and 5 frames per patch (1 shot per pixel) allowed to analyze larger zones 
of 4000 × 4000 μ m2. The mass resolution (FWHM) at m/z 15 was on average 3368 ± 83 (n = 7). The positive ion 
mass spectra were calibrated with m/z 1 (H+), 15 (CH3+), 29 (C2H5+), 43 (C3H7+) and 57 (C4H9+).
X-ray photoelectron spectroscopy (XPS) analysis of L-AME-P. XPS spectra were acquired on a Kratos Axis Ultra 
(Kratos, UK) with a monochromated Al kα source (1486.7 eV) using an emission current of 10 mA and an anode 
potential of 12 kV. Wide scans were acquired with a pass energy of 80 eV; high resolution scans were acquired 
using a pass energy of 20 eV. Charge neutralization was used. A wide scan and a high resolution C 1 s, O 1 s, N 1 s 
and Si 2p scan of three different spots on each sample were acquired. The samples were cut into 1 × 1 cm2 pieces 
using a diamond glasscutter as to fit the XPS sample holder. The XPS spectra were analyzed using CasaXPS soft-
ware (version 2.3.16).
Whole-blood kinetics with thromboelastography. Thromboelastography (TEG) on a series of L-AME 
solutions. Solutions from 0–191 mM L-AME concentration (in water) were produced. Blood was taken from 
healthy volunteers, after signing an informed consent document accordance with the regulations and as approved 
by the local (Royal Free Hospital campus) ethics committee. Blood was collected in 2.7 mL 3.0% sodium citrate 
BD Vacutainers® . 20 μ L of L-AME solution and 20 μ L of 0.2 M CaCl solution were added to a TEG cup with 320 μ L 
of citrated blood and TEG measurements (Table 3) were obtained using a TEG® 5000 Thromboelastograph® 
Hemostasis Analyzer System, and analyzed as described by Wohlauer et al.40, producing a visible tracing (SI Fig. 3).
TEG with L-AME-P polymer. Discs of polymer with a radius of 7.8 mm, were placed into the wells of a 24-well 
plate, and 500 μ L of citrated blood (obtained as described in section 2.4.2) was then pipetted into each well. The 
plate was then incubated at 37 oC for 1 hour on a PSU-10i orbital shaker at 50 RPM. After incubation, 340 μ L 
of blood was removed from each well, and added to a TEG cup that contained 20 μ L of 0.2 M CaCl solution. 
Thromboelastography was performed, and the resultant traces were extracted.
Cell-material interactions on L-AME functionalized scaffolds. Details of EPC extraction have been 
reported previously30,55. Whole blood was obtained from healthy volunteers after signing an informed consent 
document accordance with the regulations and as approved by the local (Royal Free Hospital campus) ethics 
committee. Approximately 40 ml of whole human blood was placed in 2.7 ml light blue-capped Vacutainer® 
citrate tubes (BD USA). 3 ml of Histopaque was added to six 15 ml centrifuge tubes, and 3 ml of whole blood 
was layered onto the Histopaque. The material at the opaque interface was transferred into two clean centri-
fuge tubes. 20 ml of HBSS (Life Technologies) was added, mixed gently and centrifuged at 250 g for 10 minutes. 
The supernatant was discarded and the pellet re-suspended in 5 ml HBSS and mixed gently. This centrifugation 
and supernatant-discarding process was repeated twice more. The cells were then re-suspended in 5 ml cell cul-
ture medium M199 (Life Technologies) with 10% FBS (Life Technologies), and 1% penicillin and streptavidin 
(Life Technologies). Cells were counted using Trypan blue exclusion dye, using 10 μ l Trypan blue, and 10 μ l cell 
suspension. Cells were stored in a flask at 37 °C with 5% CO2 for three days. Cells were seeded at a density of 
35 × 103cells cm−2 in a 24-well plate. . Culture medium was replenished every 3 days, and cells were examined 
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under light microscopy every 3 days. AlamarBlue® assay (Life Technologies) was performed according to stand-
ard protocol at day 5 and day 10.
Fibroblasts were grown at 37 °C with 5% CO2 for four days. . Cells were seeded at a density of 25 × 103cells cm−2 
in a 24-well plate. Culture medium was replenished every 36 h, and cells were examined under light microscopy 
every 24 h. AlamarBlue® assay (Life Technologies) was performed according to standard protocol at 36 h and 72 h 
and excitation and emission was recorded at 360 nm and 460 nm respectively. Cells on polymer were fixed in 4% 
formaldehyde stained with phalloidin (actin stain) overnight and DAPI (4′,6-diamidino-2-phenylindole) (DNA/
nucleus stain) for 10 min according to standard protocol with manufacturer-supplied instructions.
Statistics. IBM© SPSS© Statistics (Version 22) software was used to conduct analysis of variance, one-way 
ANOVA, Kruskal-Wallis and linear regression analysis.
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